|
|
|
|
Vol. 59, Issue 3, 646-654, March 2001
Medizinische Klinik und Poliklinik, Innere Medizin III,
Universitätskliniken des Saarlandes, Homburg/Saar, Germany (S.W.,
U.L., K.M., C.K., M.B., G.N.); and Klinik III für Innere Medizin
(A.T.B) and Zentrum für Physiologie und Pathophysiologie (H.S.),
Universität zu Köln, Cologne, Germany
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)
may exert pleiotropic effects on vascular cells independent of lowering
plasma cholesterol. To elucidate the molecular mechanisms involved in
these effects, we investigated the impact of statins on production of
reactive oxygen species (ROS) in rat aortic vascular smooth muscle
cells (VSMC). Exposure of VSMC to angiotensin II caused production of
ROS via angiotensin AT1 receptor activation. Pretreatment with
atorvastatin inhibited angiotensin II-induced ROS production.
Atorvastatin decreased AT1 receptor mRNA levels in a time- and
concentration-dependent manner and consistently reduced AT1 receptor
density. L-Mevalonate but not hydroxy-cholesterol reversed
the inhibitory effect of atorvastatin on AT1 receptor transcript
levels. Inhibition of geranylgeranyl-transferase but not of
farnesyl-transferase mimicked the effect of atorvastatin on AT1
receptor gene expression. Atorvastatin did not decrease AT1 receptor
gene transcription but did reduce the half-life of the AT1 receptor
mRNA. AT1 receptor activation by angiotensin II increased the
expression of the GTPase rac1, enhanced rac1 GTP-binding activity, and
increased the geranylgeranyl-dependent translocation of rac1 to the
cell membrane. In contrast, statins inhibited rac1 activity and
membrane translocation. Consequently, specific inhibition of rac1 with
Clostridium sordellii lethal toxin blocked angiotensin
II-induced production of free radicals. Finally, treatment of rats with
atorvastatin caused down-regulation of aortic AT1 receptor mRNA
expression and reduced aortic superoxide production in vivo.
Cholesterol-independent down-regulation of AT1 receptor gene expression
and inhibition of rac1, leading to decreased ROS production,
demonstrates a novel regulatory mechanism of statins that may
contribute to the beneficial effects of these drugs beyond lowering of
plasma cholesterol.
This article has been cited by other articles:
![]() |
O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Circulation, September 16, 2008; 118(12): 1285 - 1293. [Full Text] [PDF] |
||||
![]() |
H. C. Choi, P. Song, Z. Xie, Y. Wu, J. Xu, M. Zhang, Y. Dong, S. Wang, K. Lau, and M.-H. Zou Reactive Nitrogen Species Is Required for the Activation of the AMP-activated Protein Kinase by Statin in Vivo J. Biol. Chem., July 18, 2008; 283(29): 20186 - 20197. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Al-Shabrawey, M. Bartoli, A. B. El-Remessy, G. Ma, S. Matragoon, T. Lemtalsi, R. W. Caldwell, and R. B. Caldwell Role of NADPH Oxidase and Stat3 in Statin-Mediated Protection against Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3231 - 3238. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Baumer, H. ten Freyhaus, H. Sauer, M. Wartenberg, K. Kappert, P. Schnabel, C. Konkol, J. Hescheler, M. Vantler, and S. Rosenkranz Phosphatidylinositol 3-Kinase-dependent Membrane Recruitment of Rac-1 and p47phox Is Critical for {alpha}-Platelet-derived Growth Factor Receptor-induced Production of Reactive Oxygen Species J. Biol. Chem., March 21, 2008; 283(12): 7864 - 7876. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tanimoto, Y. Murata, K.-Y. Wang, M. Tsutsui, K. Kohno, and Y. Sasaguri Monocyte Chemoattractant Protein-1 Expression Is Enhanced by Granulocyte-Macrophage Colony-stimulating Factor via Jak2-Stat5 Signaling and Inhibited by Atorvastatin in Human Monocytic U937 Cells J. Biol. Chem., February 22, 2008; 283(8): 4643 - 4651. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kahles, P. Luedike, M. Endres, H.-J. Galla, H. Steinmetz, R. Busse, T. Neumann-Haefelin, and R. P. Brandes NADPH Oxidase Plays a Central Role in Blood-Brain Barrier Damage in Experimental Stroke Stroke, November 1, 2007; 38(11): 3000 - 3006. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gao, W. Wang, D. Liu, and I. H. Zucker Exercise Training Normalizes Sympathetic Outflow by Central Antioxidant Mechanisms in Rabbits With Pacing-Induced Chronic Heart Failure Circulation, June 19, 2007; 115(24): 3095 - 3102. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mangat, S. Agarwal, and C. Rosendorff Do Statins Lower Blood Pressure? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 112 - 123. [Abstract] [PDF] |
||||
![]() |
M. Cimino, P. Gelosa, A. Gianella, E. Nobili, E. Tremoli, and L. Sironi Statins: Multiple Mechanisms of Action in the Ischemic Brain Neuroscientist, June 1, 2007; 13(3): 208 - 213. [Abstract] [PDF] |
||||
![]() |
M. Sugita, H. Sugita, and M. Kaneki Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1390 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Elton and M. M. Martin Angiotensin II Type 1 Receptor Gene Regulation: Transcriptional and Posttranscriptional Mechanisms Hypertension, May 1, 2007; 49(5): 953 - 961. [Full Text] [PDF] |
||||
![]() |
S. C. Fagan, H. F. Elewa, and D. J. Rychly Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice Journal of Pharmacy Practice, April 1, 2007; 20(2): 117 - 122. [Abstract] [PDF] |
||||
![]() |
C. Schindler, K. B. Brosnihan, C. M. Ferrario, P. Bramlage, U. Maywald, R. Koch, R. Oertel, and W. Kirch Comparison of Inhibitory Effects of Irbesartan and Atorvastatin Treatment on the Renin Angiotensin System (RAS) in Veins: A Randomized Double-Blind Crossover Trial in Healthy Subjects J. Clin. Pharmacol., January 1, 2007; 47(1): 112 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Zucker Novel Mechanisms of Sympathetic Regulation in Chronic Heart Failure Hypertension, December 1, 2006; 48(6): 1005 - 1011. [Full Text] [PDF] |
||||
![]() |
F. Custodis, M. Eberl, H. Kilter, M. Bohm, and U. Laufs Association of RhoGDI{alpha} with Rac1 GTPase mediates free radical production during myocardial hypertrophy Cardiovasc Res, July 15, 2006; 71(2): 342 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Morimoto, W. J. Janssen, M. B. Fessler, K. A. McPhillips, V. M. Borges, R. P. Bowler, Y.-Q. Xiao, J. A. Kench, P. M. Henson, and R. W. Vandivier Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J. Immunol., June 15, 2006; 176(12): 7657 - 7665. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gao, W. Wang, Y.-L. Li, H. D. Schultz, D. Liu, K. G. Cornish, and I. H. Zucker Simvastatin Therapy Normalizes Sympathetic Neural Control in Experimental Heart Failure: Roles of Angiotensin II Type 1 Receptors and NAD(P)H Oxidase Circulation, September 20, 2005; 112(12): 1763 - 1770. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zuo, M. Ushio-Fukai, S. Ikeda, L. Hilenski, N. Patrushev, and R. W. Alexander Caveolin-1 Is Essential for Activation of Rac1 and NAD(P)H Oxidase After Angiotensin II Type 1 Receptor Stimulation in Vascular Smooth Muscle Cells: Role in Redox Signaling and Vascular Hypertrophy Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1824 - 1830. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Calkin, J. M. Forbes, C. M. Smith, M. Lassila, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1903 - 1909. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Dudley Jr, N. E. Hoch, L. A. McCann, C. Honeycutt, L. Diamandopoulos, T. Fukai, D. G. Harrison, S. I. Dikalov, and J. Langberg Atrial Fibrillation Increases Production of Superoxide by the Left Atrium and Left Atrial Appendage: Role of the NADPH and Xanthine Oxidases Circulation, August 30, 2005; 112(9): 1266 - 1273. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Maeda, I. Matsuoka, T. Iwamoto, H. Kurose, and J. Kimura Down-Regulation of Na+/Ca2+ Exchanger by Fluvastatin in Rat Cardiomyoblast H9c2 Cells: Involvement of RhoB in Na+/Ca2+ Exchanger mRNA Stability Mol. Pharmacol., August 1, 2005; 68(2): 414 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Laufs, S. Wassmann, T. Czech, T. Munzel, M. Eisenhauer, M. Bohm, and G. Nickenig Physical Inactivity Increases Oxidative Stress, Endothelial Dysfunction, and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 809 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, T. Taguchi, T. Matsuo, K. Sonoda, D. Kukidome, K. Imoto, T. Nishikawa, et al. Statins Suppress Oxidized Low Density Lipoprotein-induced Macrophage Proliferation by Inactivation of the Small G Protein-p38 MAPK Pathway J. Biol. Chem., February 25, 2005; 280(8): 6627 - 6633. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Madamanchi, A. Vendrov, and M. S. Runge Oxidative Stress and Vascular Disease Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 29 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Narumiya, S. Sasaki, N. Kuwahara, H. Irie, T. Kusaba, H. Kameyama, K. Tamagaki, T. Hatta, K. Takeda, and H. Matsubara HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells Cardiovasc Res, November 1, 2004; 64(2): 331 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Li, M. Iwai, L. Wu, H.-W. Liu, R. Chen, T. Jinno, J. Suzuki, M. Tsuda, X.-Y. Gao, M. Okumura, et al. Fluvastatin Enhances the Inhibitory Effects of a Selective AT1 Receptor Blocker, Valsartan, on Atherosclerosis Hypertension, November 1, 2004; 44(5): 758 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Endres and U. Laufs Effects of Statins on Endothelium and Signaling Mechanisms Stroke, November 1, 2004; 35(11_suppl_1): 2708 - 2711. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Landmesser, N. Engberding, F. H. Bahlmann, A. Schaefer, A. Wiencke, A. Heineke, S. Spiekermann, D. Hilfiker-Kleiner, C. Templin, D. Kotlarz, et al. Statin-Induced Improvement of Endothelial Progenitor Cell Mobilization, Myocardial Neovascularization, Left Ventricular Function, and Survival After Experimental Myocardial Infarction Requires Endothelial Nitric Oxide Synthase Circulation, October 5, 2004; 110(14): 1933 - 1939. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wassmann, K. Wassmann, and G. Nickenig Modulation of Oxidant and Antioxidant Enzyme Expression and Function in Vascular Cells Hypertension, October 1, 2004; 44(4): 381 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Nickenig Should Angiotensin II Receptor Blockers and Statins Be Combined? Circulation, August 24, 2004; 110(8): 1013 - 1020. [Full Text] [PDF] |
||||
![]() |
U. Landmesser, B. Hornig, and H. Drexler Endothelial Function: A Critical Determinant in Atherosclerosis? Circulation, June 1, 2004; 109(21_suppl_1): II-27 - II-33. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, R. Luo, A. Kowluru, and G. Li Novel regulation by Rac1 of glucose- and forskolin-induced insulin secretion in INS-1 {beta}-cells Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E818 - E827. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wassmann, M. Stumpf, K. Strehlow, A. Schmid, B. Schieffer, M. Bohm, and G. Nickenig Interleukin-6 Induces Oxidative Stress and Endothelial Dysfunction by Overexpression of the Angiotensin II Type 1 Receptor Circ. Res., March 5, 2004; 94(4): 534 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gregg, F. M. Rauscher, and P. J. Goldschmidt-Clermont Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch Am J Physiol Cell Physiol, October 1, 2003; 285(4): C723 - C734. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.P. Brandes, S. Beer, T. Ha, and R. Busse Withdrawal of Cerivastatin Induces Monocyte Chemoattractant Protein 1 and Tissue Factor Expression in Cultured Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1794 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Iwanciw, M. Rehm, M. Porst, and M. Goppelt-Struebe Induction of Connective Tissue Growth Factor by Angiotensin II: Integration of Signaling Pathways Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1782 - 1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Maack, T. Kartes, H. Kilter, H.-J. Schafers, G. Nickenig, M. Bohm, and U. Laufs Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin Treatment Circulation, September 30, 2003; 108(13): 1567 - 1574. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Node, M. Fujita, M. Kitakaze, M. Hori, and J. K. Liao Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy Circulation, August 19, 2003; 108(7): 839 - 843. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lassegue and R. E. Clempus Vascular NAD(P)H oxidases: specific features, expression, and regulation Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2003; 285(2): R277 - R297. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gorin, J. M. Ricono, N.-H. Kim, B. Bhandari, G. G. Choudhury, and H. E. Abboud Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells Am J Physiol Renal Physiol, August 1, 2003; 285(2): F219 - F229. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. U. Pliquett, K. G. Cornish, J. D. Peuler, and I. H. Zucker Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure Circulation, May 20, 2003; 107(19): 2493 - 2498. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wolfrum, K. S. Jensen, and J. K. Liao Endothelium-Dependent Effects of Statins Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 729 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Laufs, O. Adam, K. Strehlow, S. Wassmann, C. Konkol, K. Laufs, W. Schmidt, M. Bohm, and G. Nickenig Down-regulation of Rac-1 GTPase by Estrogen J. Biol. Chem., February 14, 2003; 278(8): 5956 - 5962. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Anderson, J. Hubacek, D. G. Wyse, and M. L. Knudtson Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy J. Am. Coll. Cardiol., February 5, 2003; 41(3): 420 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Laufs and J. K. Liao Rapid Effects of Statins: From Prophylaxis to Therapy for Ischemic Stroke Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 156 - 157. [Full Text] [PDF] |
||||
![]() |
M. Horiuchi, T.-X. Cui, Z. Li, J.-M. Li, H. Nakagami, and M. Iwai Fluvastatin Enhances the Inhibitory Effects of a Selective Angiotensin II Type 1 Receptor Blocker, Valsartan, on Vascular Neointimal Formation Circulation, January 7, 2003; 107(1): 106 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Werner and G. Nickenig AT1 receptors in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A9 - A13. [Abstract] [PDF] |
||||
![]() |
R. De Caterina and C. Manes Inflammation in early atherogenesis: impact of ACE inhibition Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A15 - A24. [Abstract] [PDF] |
||||
![]() |
C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M. Abbate, and G. Remuzzi How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2898 - 2908. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ruiz-Velasco, C. C. Lanning, and C. L. Williams The Activation of Rac1 by M3 Muscarinic Acetylcholine Receptors Involves the Translocation of Rac1 and IQGAP1 to Cell Junctions and Changes in the Composition of Protein Complexes Containing Rac1, IQGAP1, and Actin J. Biol. Chem., August 30, 2002; 277(36): 33081 - 33091. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Delbosc, J.-P. Cristol, B. Descomps, A. Mimran, and B. Jover Simvastatin Prevents Angiotensin II-Induced Cardiac Alteration and Oxidative Stress Hypertension, August 1, 2002; 40(2): 142 - 147. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vecchione and R. P. Brandes Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice Circ. Res., July 26, 2002; 91(2): 173 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Laufs, H. Kilter, C. Konkol, S. Wassmann, M. Bohm, and G. Nickenig Impact of HMG CoA reductase inhibition on small GTPases in the heart Cardiovasc Res, March 1, 2002; 53(4): 911 - 920. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Nickenig and D. G. Harrison The AT1-Type Angiotensin Receptor in Oxidative Stress and Atherogenesis: Part II: AT1 Receptor Regulation Circulation, January 29, 2002; 105(4): 530 - 536. [Full Text] [PDF] |
||||
![]() |
G. Nickenig and D. G. Harrison The AT1-Type Angiotensin Receptor in Oxidative Stress and Atherogenesis: Part I: Oxidative Stress and Atherogenesis Circulation, January 22, 2002; 105(3): 393 - 396. [Full Text] [PDF] |
||||
![]() |
U. Landmesser and D. G. Harrison Oxidant Stress as a Marker for Cardiovascular Events: Ox Marks the Spot Circulation, November 27, 2001; 104(22): 2638 - 2640. [Full Text] [PDF] |
||||
![]() |
M. Takemoto and J. K. Liao Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1712 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wassmann, U. Laufs, D. Stamenkovic, W. Linz, J.-P. Stasch, K. Ahlbory, R. Rosen, M. Bohm, and G. Nickenig Raloxifene Improves Endothelial Dysfunction in Hypertension by Reduced Oxidative Stress and Enhanced Nitric Oxide Production Circulation, April 30, 2002; 105(17): 2083 - 2091. [Abstract] [Full Text] [PDF] |
||||